The raised full-year guidance signals accelerating momentum in the core clinical business, particularly NGS. Watch for continued margin expansion as higher-mix NGS revenue scales and operational efficiency initiatives take hold. The CEO transition to Warren Stone in January 2027 is a known event with no near-term disruption risk.
Price Chart
Executive Summary
NeoGenomics reported Q3 2026 revenue of $209M (+11% YoY), above the $207.3M consensus, and GAAP net loss narrowed to $8M from $27M a year ago. The company raised full-year 2026 revenue guidance to $807M-$809M (from $802M-$806M) and adjusted EBITDA guidance to approximately $60M (from $56M-$58M). NGS revenue grew 29% and adjusted gross margin expanded 310 bps to 49%.
Key Financial Metrics
Key Facts
- Total revenue $209M, +11% YoY, above $207.3M consensus
- Clinical revenue $195M, +13% YoY, driven by NGS growth of 29%
- GAAP net loss improved 72% to $8M from $27M in Q3 2025
- Adjusted EBITDA $19M, +53% YoY from $12M
- Adjusted net income $11M vs $4M in prior year
- GAAP gross margin expanded 340 bps to 46%; adjusted gross margin 49%, +310 bps
- Full-year 2026 revenue guidance raised to $807M-$809M from $802M-$806M
- Full-year 2026 adjusted EBITDA guidance raised to approximately $60M from $56M-$58M
- Cash and cash equivalents $139M at quarter end
- Clinical test volume +2%, average revenue per test +11% to $530
Financial Impact
Revenue beat consensus by $1.7M (0.8%); adjusted EBITDA guidance raised by ~$2M-$4M at midpoint
Risk Factors
- Accounts receivable increased to $213M from $159M at year-end 2025, a 34% rise vs 11% revenue growth, suggesting collection headwinds
- Convertible senior notes of $375M remain on the balance sheet, creating potential dilution overhang
- Leadership transition to new CEO in January 2027 introduces execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001077183-26-000078 |
| Document: neo-20261028.htm | 0001077183-26-000078 |
| Document: 0001077183-26-000078-index-headers.html | 0001077183-26-000078 |
| Document: 0001077183-26-000078-index.html | 0001077183-26-000078 |
| Document: 0001077183-26-000078.txt | 0001077183-26-000078 |
| 8-K Data (Synthetic) | 0001077183-26-000078 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 28, 2026 2d ago | 8-K | $18.08 | awaiting T+60 | awaiting T+60 | $17.38 (−3.87%) |
Oct 5, 2026 25d ago | 8-K | $16.51 | awaiting T+60 | awaiting T+60 | $17.38 (+5.30%) |
Jul 20, 2026 14w ago | 8-K | $14.45 $16.66 | ▲ +15.29% | ▲ +11.32% | $17.38 (+20.28%) |
May 22, 2026 23w ago | 8-K | $9.27 $16.66 | ▲ +79.67% | ▲ +76.94% | $17.38 (+87.49%) |
Apr 28, 2026 26w ago | 8-K | $8.96 $13.89 | ▲ +55.02% | ▲ +50.91% | $17.38 (+93.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers